US 11,918,654 B2
Solid solution compositions and use in severe pain
Robin M. Bannister, Saffron Walden (GB); John Brew, St. Albans (GB); Richard R. Reiley, III, London (GB); and Wilson Caparros Wanderley, Aylesbury (GB)
Assigned to Infirst Healthcare Limited, London (GB)
Filed by Infirst Healthcare Limited, London (GB)
Filed on Dec. 28, 2021, as Appl. No. 17/646,241.
Application 17/646,241 is a continuation of application No. 16/882,667, filed on May 25, 2020, granted, now 11,224,659.
Application 16/882,667 is a continuation of application No. 14/155,167, filed on Jan. 14, 2014, granted, now 10,695,432.
Application 14/155,167 is a continuation in part of application No. 13/365,824, filed on Feb. 3, 2012, granted, now 8,895,536, issued on Nov. 25, 2014.
Application 13/365,824 is a continuation in part of application No. PCT/GB2011/052115, filed on Oct. 31, 2011.
Application 14/155,167 is a continuation in part of application No. 13/365,828, filed on Feb. 3, 2012, granted, now 8,895,537, issued on Nov. 25, 2015.
Claims priority of provisional application 61/752,309, filed on Feb. 4, 2013.
Claims priority of provisional application 61/752,356, filed on Jan. 14, 2013.
Claims priority of application No. 1018289 (GB), filed on Oct. 29, 2010; application No. 1101937 (GB), filed on Feb. 4, 2011; application No. 1113728 (GB), filed on Aug. 10, 2011; application No. 1113729 (GB), filed on Aug. 10, 2011; and application No. 1113730 (GB), filed on Aug. 10, 2011.
Prior Publication US 2022/0118091 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/00 (2006.01); A61K 9/08 (2006.01); A61K 31/121 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/196 (2006.01); A61K 31/222 (2006.01); A61K 31/357 (2006.01); A61K 31/366 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/522 (2006.01); A61K 31/60 (2006.01); A61K 31/616 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01); A61K 47/44 (2017.01)
CPC A61K 47/14 (2013.01) [A61K 31/121 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/222 (2013.01); A61K 31/357 (2013.01); A61K 31/366 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/522 (2013.01); A61K 31/60 (2013.01); A61K 31/616 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 9/08 (2013.01); A61K 47/44 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A solid solution pharmaceutical composition comprising:
a) one or more phytocannabinoids, the one or more phytocannabinoids in an amount of less than about 55% by weight of the solid solution pharmaceutical composition;
b) one or more pharmaceutically-acceptable hard fats comprising one or more glycerolipids, the one or more pharmaceutically-acceptable hard fats in an amount of at least 25% by weight of the solid solution pharmaceutical composition;
c) one or more pharmaceutically-acceptable liquid lipids comprising one or more partially hydrolyzed fats, the one or more pharmaceutically-acceptable liquid lipids in an amount of about 1% to about 50% by weight of the solid solution pharmaceutical composition, and
wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and has a melting point of 30° C. or higher.